Corcept Therapeutics (CORT) Free Cash Flow (2010 - 2026)

Corcept Therapeutics has reported Free Cash Flow for 17 years, with the latest figure at $31.0 million in Q2 2026.

• Quarterly Free Cash Flow fell 29.89% year-over-year to $31.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $106.9 million (down 40.76% YoY) and the FY2025 annual result came in at $141.8 million, down 27.71% from the prior year.
• Free Cash Flow climbed to $31.0 million in Q2 2026 per CORT's latest filing, from -$17.0 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $71.7 million in Q3 2024 and troughed at -$17.0 million in Q1 2026.
• A 5-year average of $33.2 million and a median of $34.3 million in 2022 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2024 and 2026: Free Cash Flow jumped 984.05% in 2024, then tumbled 463.76% in 2026.
• Over 5 years, Free Cash Flow stood at $33.4 million in 2022, then plunged by 83.42% to $5.5 million in 2023, then surged by 984.05% to $59.9 million in 2024, then plunged by 35.94% to $38.4 million in 2025, then slipped by 19.23% to $31.0 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $31.0 million, -$17.0 million, and $38.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.